DekaBank Deutsche Girozentrale’s BridgeBio Pharma BBIO Stock Holding History

DekaBank Deutsche Girozentrale’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.91M	Hold	100,000	–	–	0.01%	503
2026 Q1	$7.05M	Hold	100,000	–	–	0.01%	504
2025 Q4	$3.35M	Hold	100,000	–	–	0.01%	663
2025 Q3	$5.17M	Hold	100,000	–	–	0.01%	570
2025 Q2	$4.48M	Hold	100,000	–	–	0.01%	589
2025 Q1	$3.43M	Hold	100,000	–	–	0.01%	635
2024 Q4	$2.73M	Hold	100,000	–	–	0.01%	694
2024 Q3	$2.48M	Hold	100,000	–	–	﹤0.01%	714
2024 Q2	$2.51M	Hold	100,000	–	–	﹤0.01%	713
2024 Q1	$3.08M	Hold	100,000	–	–	0.01%	675
2023 Q4	$4.15M	Hold	100,000	–	–	0.01%	621
2023 Q3	$2.7M	Hold	100,000	–	–	0.01%	674
2023 Q2	$1.7M	Hold	100,000	–	–	﹤0.01%	787
2023 Q1	$1.71M	Buy	100,000 +50,000	+100%	+$583K	﹤0.01%	751
2022 Q4	$373K	Hold	50,000	–	–	﹤0.01%	1104
2022 Q3	$500K	Buy	50,000 +10,200	+26%	+$106K	﹤0.01%	1043
2022 Q2	$344K	Hold	39,800	–	–	﹤0.01%	1090
2022 Q1	$413K	Buy	39,800 +3,600	+10%	+$36.9K	﹤0.01%	1095
2021 Q4	$517K	Buy	36,200 +1,000	+3%	+$42.3K	﹤0.01%	1089
2021 Q3	$1.65M	Sell	35,200 -18,000	-34%	-$965K	﹤0.01%	768
2021 Q2	$3.13M	Hold	53,200	–	–	0.01%	636
2021 Q1	$3.09M	Buy	53,200 +15,000	+39%	+$981K	0.01%	598
2020 Q4	$2.54M	Sell	38,200 -1,900	-5%	-$91.7K	0.01%	612
2020 Q3	$1.45M	Buy	+40,100	New	+$1.26M	0.01%	665

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

DekaBank Deutsche Girozentrale's BBIO Position: Q2 2026 in Review

DekaBank Deutsche Girozentrale held its BridgeBio Pharma (BBIO) position steady in Q2 2026 at 100,000 shares worth $6.91M. The position accounts for 0.01% of the portfolio, ranked #503.

DekaBank Deutsche Girozentrale first reported a position in BBIO in Q3 2020 and has held it in 24 quarters since. The position peaked at $7.05M in Q1 2026. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

DekaBank Deutsche Girozentrale held 100,000 shares of BridgeBio Pharma worth $6.91M as of Q2 2026.
DekaBank Deutsche Girozentrale left its BridgeBio Pharma share count unchanged in Q2 2026.
BridgeBio Pharma made up 0.01% of DekaBank Deutsche Girozentrale's portfolio in Q2 2026, its #503 holding.
DekaBank Deutsche Girozentrale first reported a position in BridgeBio Pharma in Q3 2020 and has held it in 24 quarters since.
DekaBank Deutsche Girozentrale's BridgeBio Pharma position peaked at $7.05M in Q1 2026.
474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on DekaBank Deutsche Girozentrale's 13F filing for Q2 2026, filed 5 Aug 2026.